Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 3/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.58 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.58 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.58 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.58 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496233 | 0.90 | PRKAB2 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4502136 | 0.88 | GSK3B (0.60) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4496851 | 0.83 | GSK3B (0.55) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1378100 | 0.82 | GSK3B (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4493589 | 0.81 | GSK3B (0.54) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4503888 | 0.81 | FADS1 (0.59) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4492488 | 0.80 | GSK3B (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4497832 | 0.80 | GSK3B (0.61) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4492720 | 0.79 | GSK3B (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4497721 | 0.78 | GSK3B (0.52) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537087-B1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2012-11-28 | — | — | EP | claimed |
| JP-4648703-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| US-7166629-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | claimed |
| JP-2006503824-A | — | — | 2006-02-02 | — | — | JP | claimed |
| EP-1537087-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2005-06-08 | — | — | EP | claimed |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | AVENTIS PHARMA S.A. (FR) | 2004-06-10 | — | — | US | claimed |
| WO-2004022544-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2004-03-18 | — | — | WO | claimed |
| EP-1537087-B1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2012-11-28 | — | — | EP | disclosed |
| US-7582669-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA SA (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20070093479-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7166629-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| EP-1537087-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | AVENTIS PHARMA S.A. (FR) | 2004-06-10 | — | — | US | disclosed |
| WO-2004022544-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093479-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SUCNR1, CNR1, SIGMAR1 | PRKAB2 4662/4885PRKAG1 4551/4885PRKAA2 3581/4885 |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | OXSR1, OXER1, OXGR1 | PRKAB2 3630/4885PRKAG1 3223/4885PRKAA2 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.